I agree that Leo having complete pricing flexibili
Post# of 72440
You said, “If Brilacidin performs at a similar efficacy in human trials as proven in labs (80% more effective in viral reduction as Remdesivir) and Leo decides to price below Remdesivir it will be a no-brainer for the U.S. government to endorse Brilacidin as the top CV19 treatment.
Read More: https://investorshangout.com/post/viewall?id=...40FwW3B”